The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate

Bone

Volumn 64, Issue , 2014, Pages 57-64

  Bajaj, Devendra ^a   Geissler, Joseph R ^a,b   Allen, Matthew R ^c   Burr, David B ^c   Fritton, J C ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiresorptives; Atypical fracture; Bone remodeling; Osteocytes; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE FRAGILITY; BONE INJURY; BONE REMODELING; BONE STRUCTURE; CELL DENSITY; CORTICAL BONE; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DOG; DRUG MEGADOSE; FATIGUE; FEMALE; FRACTURE; LOADING TEST; MORPHOMETRICS; NONHUMAN; OSTEOCYTE; YOUNG MODULUS; ANIMAL; BONE; DRUG EFFECTS; MECHANICAL STRESS; PHYSIOLOGY;

ALENDRONATE; ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOGS; FEMALE; STRESS, MECHANICAL;

EID: 84899144899     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.03.045     Document Type: Article

References (57)

1. FDA Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee September 9, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf.
2. Rodan G.A., Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97:2692-2696.
3. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996, 348:1535-1541.
4. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T.A., Hochberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial research group. J Clin Endocrinol Metab 2000, 85:4118-4124.
5. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998, 280:2077-2082.
6. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 1995, 333:1437-1443.
7. Mackey D.C., Black D.M., Bauer D.C., McCloskey E.V., Eastell R., Mesenbrink P., et al. Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res 2011, 26:2411-2418.
8. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3years of daily treatment. Calcif Tissue Int 2008, 82:354-360.
9. Bala Y., Depalle B., Farlay D., Douillard T., Meille S., Follet H., et al. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 2012, 27:825-834.
10. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
11. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
12. Donnelly E., Meredith D.S., Nguyen J.T., Gladnick B.P., Rebolledo B.J., Shaffer A.D., et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012, 27:672-678.
13. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
14. Gourion-Arsiquaud S., Allen M.R., Burr D.B., Vashishth D., Tang S.Y., Boskey A.L. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 2010, 46:666-672.
15. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
16. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
17. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
18. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Jacob D.S., Johnston C.C., et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
19. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894.
20. Tjhia C.K., Stover S.M., Rao D.S., Odvina C.V., Fyhrie D.P. Relating micromechanical properties and mineral densities in severely suppressed bone turnover patients, osteoporotic patients, and normal subjects. Bone 2012, 51:114-122.
21. Burr D.B., Martin R.B., Schaffler M.B., Radin E.L. Bone remodeling in response to in vivo fatigue microdamage. J Biomech 1985, 18:189-200.
22. Lee T.C., Staines A., Taylor D. Bone adaptation to load: microdamage as a stimulus for bone remodelling. J Anat 2002, 201:437-446.
23. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
24. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
25. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
26. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
27. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783-789.
28. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
29. Somford M.P., Draijer F.W., Thomassen B.J.W., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736-1740.
30. Dell R.M., Adams A.L., Greene D.F., Funahashi T.T., Silverman S.L., Eisemon E.O., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012, 27:2544-2550.
31. Burr D.B., Turner C.H., Naick P., Forwood M.R., Ambrosius W., Hasan M.S., et al. Does microdamage accumulation affect the mechanical properties of bone?. J Biomech 1998, 31:337-345.
32. Carter D.R., Hayes W.C., Schurman D.J. Fatigue life of compact bone-II. Effects of microstructure and density. J Biomech 1976, 9:211-218.
33. Hoshaw S.J., Cody D.D., Saad A.M., Fyhrie D.P. Decrease in canine proximal femoral ultimate strength and stiffness due to fatigue damage. J Biomech 1997, 30:323-329.
34. Pattin C.A., Caler W.E., Carter D.R. Cyclic mechanical property degradation during fatigue loading of cortical bone. J Biomech 1996, 29:69-79.
35. Schaffler M.B., Radin E.L., Burr D.B. Long-term fatigue behavior of compact bone at low strain magnitude and rate. Bone 1990, 11:321-326.
36. Landrigan M.D., Roeder R.K. Systematic error in mechanical measures of damage during four-point bending fatigue of cortical bone. J Biomech 2009, 42:1212-1217.
37. Boyce T.M., Fyhrie D.P., Glotkowski M.C., Radin E.L., Schaffler M.B. Damage type and strain mode associations in human compact bone bending fatigue. J Orthop Res 1998, 16:322-329.
38. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2013, 28:2-17.
39. Scholz F.W., Stephens M.A. K-sample Anderson-Darling tests. J Am Stat Assoc 1987, 82:918-924.
40. Diab T., Vashishth D. Effects of damage morphology on cortical bone fragility. Bone 2005, 37:96-102.
41. Tjhia C.K., Odvina C.V., Sudhaker R.D., Stover S.M., Wang X., Fyhrie D.P. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011, 49:1279-1289.
42. Frost H.M. Human Haversian system measurements. Henry Ford Hosp Med Bull 1961, 9:145-147.
43. Jaworski Z.F. Lamellar bone turnover system and its effector organ. Calcif Tissue Int 1984, 36(S1):S46-S55.
44. Burr D.B., Schaffler M.B., Frederickson R.G. Composition of the cement line and its possible mechanical role as a local interface in human compact bone. J Biomech 1988, 21:939-945.
45. Koester K.J., Ager J.W., Ritchie R.O. The true toughness of human cortical bone measured with realistically short cracks. Nat Mater 2008, 7:672-677.
46. Lakes R., Saha S. Cement line motion in bone. Science 1979, 204:501-503.
47. Qiu S., Rao D.S., Palnitkar S., Parfitt A.M. Dependence of bone yield (volume of bone formed per unit of cement surface area) on resorption cavity size during osteonal remodeling in human rib: implications for osteoblast function and the pathogenesis of age-related bone loss. J Bone Miner Res 2010, 25:423-430.
48. Qiu S., Rao D.S., Palnitkar S., Parfitt A.M. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 2003, 18:1657-1663.
49. Schaffler M.B., Choi K., Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone 1995, 17:521-525.
50. Norman T.L., Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 1997, 20:375-379.
51. Ruppel M.E., Burr D.B., Miller L.M. Chemical makeup of microdamaged bone differs from undamaged bone. Bone 2006, 39(2):318-324.
52. Poundarik A.A., Diab T., Sroga G.E., Ural A., Boskey A.L., Gundberg C.M., et al. Dilatational band formation in bone. Proc Natl Acad Sci U S A 2012, 109:19178-19183.
53. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
54. Allen M.R., Erickson A.M., Wang X., Burr D.B., Martin R.B., Hazelwood S.J. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int 2010, 86:67-71.
55. Boyce R.W., Paddock C.L., Gleason J.R., Sletsema W.K., Eriksen E.F. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 1995, 10:211-221.
56. Eriksen E.F. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010, 11:219-227.
57. Jowsey J. Studies of Haversian systems in man and some animals. J Anat 1966, 100:857-864.